(Q38606230)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

PPARγ Regulation in Hypertension and Metabolic Syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Madeliene Stump

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Masashi Mukohda

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Chunyan Hu

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

1 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

Current Hypertension Reports

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

PPAR delta: a dagger in the heart of the metabolic syndrome

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

The roles of peroxisome proliferator-activated receptors in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPAR gamma and human metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Obesity, inflammation, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Vascular Smooth Muscle Cell Peroxisome Proliferator–Activated Receptor-γ Mediates Pioglitazone-Reduced Vascular Lesion Formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-γ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPARγ is an E3 ligase that induces the degradation of NFκB/p65.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Can PPARgamma agonists have a role in the management of obesity-related hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Effects of thiazolidinediones on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Interference with peroxisome proliferator-activated receptor-γ in vascular smooth muscle causes baroreflex impairment and autonomic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Role of peroxisome proliferator-activated receptor-γ in vascular muscle in the cerebral circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPARγ regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Genetic interference with peroxisome proliferator-activated receptor γ in smooth muscle enhances myogenic tone in the cerebrovasculature via A Rho kinase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Characterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPARgamma in endothelial cells influences high fat diet-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPAR-gamma regulates osteoclastogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

KLF11 mediates PPARγ cerebrovascular protection in ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Adiponectin protein exists in aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Troglitazone action is independent of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

A role for central nervous system PPAR-γ in the regulation of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Leptin and the regulation of body weight in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Signals that regulate food intake and energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Studies on the physiological functions of the melanocortin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPARγ ablation sensitizes proopiomelanocortin neurons to leptin during high-fat feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Peroxisome proliferator-activated receptor γ controls ingestive behavior, agouti-related protein, and neuropeptide Y mRNA in the arcuate hypothalamus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Incidence and mortality of hip fractures in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

GQ-16, a Novel Peroxisome Proliferator-activated Receptor (PPAR ) Ligand, Promotes Insulin Sensitization without Weight Gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPARγ: no SirT, no service.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Aspects of the regulatory mechanisms of PPAR functions: analysis of a bidirectional response element and regulation by sumoylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

PPARγ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0601-X

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

21 January 2018

1 reference

12 December 2020

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

1 reference

12 December 2020

The dawn of the SPPARMs?

1 reference

12 December 2020

PPARgamma in the control of brown adipocyte differentiation.

1 reference

12 December 2020

Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

1 reference

12 December 2020

PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice

1 reference

12 December 2020

Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production

1 reference

12 December 2020

PPAR-γ action: it's all in your head

1 reference

12 December 2020

Hypertension-causing Mutations in Cullin3 Protein Impair RhoA Protein Ubiquitination and Augment the Association with Substrate Adaptors.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation

1 reference

12 December 2020

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

1 reference

12 December 2020

10.1007/S11906-015-0601-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26462805%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

PubMed publication ID

26462805

1 reference